SXSW takes a pulse on what is hot in technology and popular culture for the coming year, and several trends emerged that pharma can begin working with now. Here’s what we saw at SXSW and what you need to know about it.

Consolidation is driven by larger pharma companies snapping up smaller players to access new therapies recently approved by the FDA or in clinical development. In addition, Private equity firms are taking a stake in ownership while also funding biotech and emerging pharmaceutical companies.